؉ cells. These data suggest that MMPs may be important regulatory proteases in attenuating SDF-1 function and point to a deep convergence of two important networks, chemokines and MMPs, to regulate leukocytic activity in vivo.
Chemokines are a super-family of structurally related chemoattractant cytokines critical for the directed migration of leukocytes (1) . Two main families are classified by the spacing of the first two cysteine residues: i) the CC chemokine family that includes monocyte chemoattractant proteins (MCP)
1 -1 to -4 (2) and macrophage inflammatory peptide-1␣ and ␤ (3), ii) and the CXC chemokine family that includes interleukin (IL)-8 (4), neutrophil-activating peptide (NAP)-2 (5), and stromal cellderived factor (SDF)-1␣ and ␤ (6). The two SDF-1 isoforms (␣ and ␤) of 67 and 72 amino acid residues, respectively, differ only at the C terminus due to differential splicing of a single gene. SDF-1 binds a specific cell surface receptor, CXCR-4, and is a potent chemoattractant for a variety of cells including resting T lymphocytes, monocytes, and CD34 ϩ stem cells. One of the primary roles of SDF-1␣ and its cognate receptor is in the homing, retention, and maturation of early progenitor cells in the bone marrow (7), a major source of SDF-1␣. However, SDF-1␣ is also involved in other cellular functions as demonstrated from gene-disruption studies (8) . Both SDF-1␣ and CXCR-4 knock-out mice exhibit similar phenotypes: they die in utero with severe developmental defects in the immune, circulatory, and central nervous systems (9) indicating that this chemokine has important roles outside of the immune system. Human immunodeficiency virus (HIV)-1 entry into CD4-expressing target cells is dependent upon binding CXCR-4 (10) or CCR-5 (11) , which are coreceptors for the T-tropic and M-tropic strains of HIV, respectively. That CXCR-4 interaction is required for viral entry is demonstrated by the ability of SDF-1␣ and synthetic CXCR-4-antagonist analogues to inhibit HIV infection (12, 13) . Tumor cell CXCR-4 expression has also been very recently shown to target circulating metastatic breast cancer cells to sites with high SDF-1 levels, such as bone and brain (14) .
In vivo, chemokines form chemoattractant gradients at very low tissue concentrations aided by binding and immobilization to glycosaminoglycan (GAG) side-chains of extracellular matrix proteoglycans. Chemokine activity is also regulated by chemokine and chemokine receptor expression, plasma membrane trafficking, endocytosis, and by proteolysis by CD 26 (15) and matrix metalloproteinases (MMPs) of CC chemokines (16) to modulate cellular responsiveness. MMPs are zinc-dependent endoproteinases with extracellular matrix-degrading activity that has been well characterized in vitro (17) . While this may prove to be an important aspect of MMP biology for the removal of large amounts of extracellular matrix in processes such as uterus involution and severe inflammatory disorders, evidence for the role of secreted MMPs in normal tissue remodeling and cell migration is extremely limited (18) . Apart from MT1-MMP, knock-out mice of MMPs display remarkably minimal effects on matrix degradation, and only a few reports have demonstrated MMP cleavage products of matrix components in vivo (19, 20) . However, growing evidence shows that specific proteolysis and processing of both cell surface and secreted factors by MMPs alters the biological activity of these substrates. Examples of MMP-mediated release or activation of cytokines include Fas ligand (21), TNF-␣ (22), the ectodomain of the fibroblast growth factor receptor-1 (23), the heparin-binding epidermal growth factor (24) , and IL-8 (25) . Soluble factors that are cleaved and inactivated by MMPs include IL-1␤ (26), insulin-like growth factor binding proteins (27) , fibrinogen and factor XII (28) , and the CC chemokine MCP-3 (16) .
Since MCP-3 and IL-8 are processed by MMPs, we hypothesized that other chemokines may also be novel substrates in the MMP degradome. Here, we have characterized the N-terminal processing of the CXC chemokine SDF-1 by MMP activity. The MMP-mediated removal of the first four residues of SDF-1␣ results in loss of CXCR-4 binding and agonist activity with a commensurate loss of ability to block HIV infection of CD4 ϩ cells. This report presenting a new example of chemokine processing leading to inactivation by MMP activity and the first for CXC chemokine inactivation further suggests that MMPs may also process other chemokines in both the CXC and CC chemokine families. Hence, MMP proteolysis of chemokines may be an important emerging function of MMPs in vivo to control leukocyte migration and activity in a variety of normal processes and pathologies.
EXPERIMENTAL PROCEDURES
Proteins-Human SDF-1␣, SDF-1␣-(5-67) (corresponding to a truncated form of SDF with an N terminus at position 5), SDF-1␤, NAP-2, IL-8, MCP-1, and MCP-3 were chemically synthesized and purified as previously described (29) . Recombinant human MMP-2 (gelatinase A, EC 3.4.24.24) was expressed from Chinese hamster ovary cells and purified from the conditioned medium as recently described (30) . A catalytically inactive form of human MMP-2 (E375A) was prepared, expressed, and purified. 2 Recombinant-purified MMP-1, -3, -7, -8, -9, -13, and -14 were expressed and purified by standard techniques (30, 31) or were the generous gift of British Biotech Pharmaceuticals Ltd. (Oxford, United Kingdom). Recombinant His 6 -tagged MMP-2 hemopexin C domain (32) and collagen-binding domain comprised of three fibronectin type II repeats (33) were expressed and purified from Escherichia coli as previously described (31) Enzyme Assays-Screening for chemokine cleavage was performed at an enzyme/substrate ratio of 1:100 (w/w) and kinetic analyses were performed at 1:1000 (w/w). All assays were performed at 37°C in CAB (150 mM NaCl, 20 mM Tris, 5 mM CaCl 2 , pH 7.5). The additions of various exogenous MMP and TIMP protein domains were as indicated in figure legends. The synthetic hydroxamate MMP inhibitor BB-2275 was from British Biotech Pharmaceuticals Ltd. Reaction products were electrophoresed in 15% Tris-tricine SDS-PAGE gels and stained with Coomassie Brilliant Blue R-250. Electrospray mass spectrometry confirmed cleavage (16) , and the measured mass was used to identify the scissile bond.
Enzyme-linked Immunosorbent Assays-SDF-1␣ or MCP-3 were bound to 96-well plates in Vollers buffer (100 mM sodium bicarbonate, pH 9.5) at 4°C for 16 h. Remaining protein binding sites were blocked with 2.5% bovine serum albumin in phosphate-buffered saline (PBS) (140 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 ϫ 7H 2 O, 1.5 mM KH 2 PO 4 , pH 7.4), at 22°C for 1 h. Recombinant MMP-2 hemopexin C domain or MMP-2 collagen-binding domain (5 ϫ 10 Ϫ11 M Ϫ 5 ϫ 10 Ϫ5 M) were added and incubated at 22°C for 1 h. Following extensive washes, affinitypurified anti-His 6 antibody was added and incubated at 22°C for 1 h. Binding was assessed by addition of horseradish peroxidase-conjugated secondary antibody and p-nitrophenyl reagent (Sigma) and measuring the absorbance at 405 nm on a plate reader (Molecular Devices) (33) .
I-MCP-3 Column
Chromatography-Catalytically inactive MMP-2(E375A) without the pro-peptide was immobilized onto gelatin-Sepharose resin. Following a blocking step with bovine serum albumin, four 50-l mini-columns were prepared.
125
I-MCP-3 was loaded and allowed to bind to the immobilized MMP-2 (via interaction with the hemopexin C domain and active site cleft). Following extensive washes with PBS, 10 g/100 l SDF-1␣ or MCP-3 were added in PBS, followed by a PBS wash. Elution of bound 125 I-MCP-3 by the unlabeled SDF-1 or MCP-3 was compared with MCP-1 (which does not bind MMP-2 (16)) or PBS alone loaded on control columns. Fractions were assessed for radioactivity by monitoring counts per minute in a gamma-counter (Beckman).
Cell-binding Assays-The murine pre-B lymphoma cell line B300 -19 was transfected with linearized SRalpha-puro plasmid containing the human CXCR-4 cDNA, and clones stably expressing CXCR-4 were selected as described (34) . About 5000 receptors/cell are expressed on the cell surface. I-SDF-1␣ in the cell pellet was measured by gamma counting. Nonspecific binding was determined in the presence of a 100-fold concentration of unlabeled ligand and was subtracted from the total.
HIV Inhibition Assays-HeLa cells transfected with human CD4, were infected with the CXCR4-using virus strain NL4 -3 at an input titer of 1.03 focus forming units/cell as previously described (35) . Cells were infected in the presence of SDF-1␣-(1-67) or SDF-1␣-(5-67) at different concentrations for 24 h and subsequently fixed in 95% ethanol. Immunostaining using a monoclonal antibody to HIV-1 p24 was performed, and positive foci were counted per unit area. Results were normalized to counts from untreated infected cultures, and all experiments were performed in triplicate wells and repeated twice.
Chemotaxis Assays-Normal bone marrow was obtained from allogeneic bone marrow donors in accordance with approved Institutional Ethics protocols. CD34 ϩ bone marrow progenitors were purified from normal bone marrow mononuclear cells isolated on Ficoll Hypaque. Cells were labeled with anti-CD34-biotin (QBEND10) and streptavidinparamagnetic microbeads under serum-free conditions. CD34 ϩ cells were purified by two sequential passes through a MACS column (36) (Becton Dickinson, Mountainview, PA) according to the manufacturer's instructions.
NALM-6 or CD34 ϩ stem cells (37) were plated (5 ϫ 10 4 cells/100 l) in transwell inserts containing eight micron pores (Costar, Corning, NY). Peptides were added to the lower chamber at the concentrations indicated in figure legends. Plates were incubated at 37°C for 4 h, and migrated NALM-6 cells were enumerated by flow cytometry in a FACSCalibur. Migrated CD34 ϩ cells were enumerated by labeling with an anti-CD34 antibody (HPCA-2) followed by flow cytometry.
Cell Culture Assays-Cultures of monocytic U937 cells were coincubated with SDF-1␣ in the presence or absence of blocking antibody to human MMP-2 (NeoMarkers). The conditioned culture medium at 24 h (n ϭ 3) and 48 h (n ϭ 3) was harvested and subjected to mass spectroscopic analysis (16) .
RESULTS

SDF-1␣ and ␤ Are Efficiently Cleaved by MMP-2-Proteo-
lytic screening with MMPs of a number of CXC chemokines including IL-8 and NAP-2, which were not cleaved, revealed that SDF-1␣ and SDF-1␤ were novel substrates for MMP-2 ( Fig. 1, A and B) . N-TIMP-2, the inhibitory domain of the specific tissue inhibitor of metalloproteinase-2 or the synthetic hydroxamate metalloproteinase inhibitor BB-2275 prevented cleavage. Electrospray mass spectrometry analysis of the reaction products identified the scissile bond in both SDF-1␣ and ␤ to be Ser 4 -Leu 5 ( Fig. 1) . We designate these products SDF-1␣-(5-67) and SDF-1␤-(5-72). Hence, MMP-2 activity removes a tetrapeptide from the SDF-1 N terminus at an analogous site to MMP-2 proteolysis of MCP-3 (16) . When the generation of cleavage product over time was monitored on Tris-tricine gels (Fig. 1C) , the MMP-2-mediated cleavage of SDF-1␣ occurred with very similar kinetics to MCP-3, which is among the most efficiently cleaved substrates of MMP-2 (16). This confirms that MMP-2 has potent activity against SDF-1.
SDF-1␣ Binds the Hemopexin C Domain of MMP-2-MMPs are multidomain enzymes comprised of a catalytic domain, a hemopexin C domain, and for MMP-2 and MMP-9 (gelatinases A and B), a fibronectin-like collagen-binding domain. Using recombinant domains of MMP-2 we localized the SDF-1␣ binding site. SDF-1␣ binds with saturation to the hemopexin C domain of MMP-2 with higher relative affinity than MCP-3 ( Fig. 2A) . Specificity was shown by the absence of significant binding to the collagen-binding domain of the enzyme. Confirming the importance of binding of SDF-1␣ to the MMP-2 hemopexin C domain for catalysis we found that at a 5:1 molar ratio the hemopexin C domain, but not the collagen-binding domain, completely inhibited MMP-2 cleavage of SDF-1␣. Fig.  2B shows Tris-tricine gel electrophoretic and electrospray mass spectroscopic analyses of the reaction products in these competition assays.
The SDF-1␣ Binding Site on the Hemopexin C Domain Overlaps the MCP-3 Binding Site-Exosite binding and presentation of substrate to the active site is an important aspect of proteolysis by MMPs (38) . We aimed to determine whether the binding site for SDF-1␣ on the hemopexin C domain is distinct from the MCP-3 exosite. To do this we engineered an "activated" form (lacking only the pro-peptide region) of the MMP-2 enzyme in which the catalytic glutamic acid was replaced with alanine. This mutant enzyme is no longer active but can be immobilized onto gelatin-Sepharose resin to which MMP-2 binds via the collagen-binding domain (33) .
125 I-MCP-3, which we have previously shown binds the hemopexin C domain (16) , was then bound to the immobilized enzyme. Since the enzyme is catalytically inactive the chemokine is not cleaved and so remains bound. Unlabeled SDF-1␣ competed the 125 I-MCP-3 off the hemopexin C domain of MMP-2 as demonstrated by release of radioactivity into column fractions following addition of SDF-1␣, but not PBS (Fig. 3) . As a positive control, competition with MCP-3 also resulted in release of radioactivity from the column. MCP-1, which does not bind the MMP-2 hemopexin C domain, did not release significant counts from the column. These data indicate that at least part of the SDF-1␣ exosite is shared with the MCP-3 exosite on the hemopexin C domain.
SDF-1␣-(5-76) Affinity for CXCR-4 -
To assess the biological activity of the MMP-2-cleaved form of SDF-1␣, we measured the binding of full-length SDF-1␣-(1-67) and synthesized SDF-1␣-(5-67) to pre-B cells transfected with the SDF-1␣ chemokine receptor, CXCR-4, by competition experiments using 125 I-SDF-1␣. SDF-1␣-(5-67) had greatly reduced affinity for the receptor whereas SDF-1␣-(1-67) bound with high affinity (Fig.  4A) . Scatchard analysis of the data determined a K d of 6 nM for SDF-1␣-(1-67) as found before (39) . Due to weak cell binding it was difficult to derive an accurate K d for SDF-1␣-(5-67). However, we estimated at least a 100-fold reduction in receptor affinity for SDF-1␣-(5-67). At this concentration SDF-1␣-(5-67) was unable to stimulate migration of either pre-B NALM-6 cells (Fig. 5A ) or CD34 ϩ hematopoietic progenitor cells (Fig. 5B) . Statistical analysis showed that chemotaxis of CD34 ϩ cells at all concentrations of SDF-1␣-(5-67) was not significantly different from the control or 200 nM SDF-1␣-(5-67).
SDF-1␣-(5-76) Does Not Inhibit HIV-1 Infection-To
Proteoglycans Do Not Protect SDF-1␣ from MMP-2 Cleavage-Like most chemokines, SDF-1␣ has affinity for the GAG side-chains of many proteoglycans. This association with functional groups of the extracellular matrix may aid in the stabilization of chemotactic gradients in the extracellular milieu, as well as facilitate the presentation of the chemokine to cellular receptors. To test whether interaction of SDF-1␣ with extracellular matrix proteoglycans modulated or masked susceptibility to MMP-2 cleavage we incubated SDF-1␣ with a molar excess of the proteoglycan, aggrecan, and the GAGs chondroitin sulfate, hyaluronan, or heparan sulfate before addition of MMP-2. Tris-tricine gel analysis revealed no protection of SDF-1␣ from cleavage by MMP-2 (Fig. 6A) . The presence of the highly anionic chondroitin sulfate consistently reduced the electrophoretic mobility of the chemokine. Electrospray mass spectrometry performed to support the gel analyses, confirmed full cleavage of SDF-1␣ in the presence of all GAGs and aggrecan. These data are consistent with the proposal that chemokine interaction with extracellular matrix components is mediated through the C-terminal regions (40) , which as our data shows, does not prevent MMP cleavage of the N terminus.
SDF-1 Is Cleaved by Multiple MMPs in Vitro and in Cell
Culture-The specificity of SDF-1␣ and ␤ cleavage by MMPs was assessed. Incubation of both SDF-1␣ and ␤ with MMP-1, -3, -9, -13, and -14 resulted in a similar increase in electrophoretic mobility on Tris-tricine gels as SDF-1 cleaved by MMP-2 (Fig. 6B) . Mass spectrometry analysis confirmed cleavage and identified the scissile bond to be Ser 4 -Leu 5 in all cases. In contrast, MMP-7 and -8 were unable to cleave either SDF-1␣ or ␤. 
DISCUSSION
Chemokines are important regulators of leukocyte migration and function. For some chemokines maintenance of expression levels is critical for normal immune system function and tissue homeostasis, for others acute release induces transient fluxes of leukocyte migration in tissues. Indeed, inappropriate chemotactic signals are a contributing factor to pathological conditions including arthritis and fibrosis (42) . In many pathologies disturbances in the proteinase/inhibitor balance leads to extracellular matrix destruction with MMPs proposed to be important effectors of this process. MMP activity is also critical for leukocyte and tumor cell migration (43) (44) (45) . Here we have investigated the proteolytic processing by MMPs of the CXC chemokine SDF-1␣, a chemokine important for hematopoietic progenitor stem cell migration (7) and for breast cancer metastasis (14) .
MMP-2 efficiently converts SDF-1␣ from a potent chemoattractant and HIV antagonist to a molecule, SDF-1␣-(5-67), devoid of biological activity. Six of eight MMPs tested could cleave SDF-1␣ and ␤ at position 4 -5, and this redundancy suggests that physiologically SDF-1␣ cleavage in vivo is very likely a consequence of MMP expression. Indeed, MMP activity is present in bone marrow upon stimulation (46) and in inflammation of the brain (47) . The presence of a MMP-susceptible bond at position 4 -5 in SDF-1␣ as well as MCP-3 (16) and MCP-1, -2, and -4 3 indicates that this may be a feature present in many chemokine sequences leading to widespread MMP cleavage susceptibility and resultant modulation of activity throughout the chemokine superfamily.
Binding and cleavage specificities of MMPs is expanded by utilizing substrate-binding exosites on domains outside the catalytic domain (38) . Our previous study showed the importance of the hemopexin C domain in binding MCP-3 (16) and here we demonstrate that it also binds SDF-1␣. Moreover, the binding site for SDF-1␣ overlaps that for MCP-3 as shown by competition studies. This supports the hypothesis that a common chemokine-binding exosite is present on the MMP-2 hemopexin C domain. From the crystal structure of human MMP-2 (48), a potential substrate-binding groove is formed at the contact face between the catalytic and hemopexin C domains. Molecular modeling suggests that this cleft may bind MCP-3 and from our competition experiments may therefore also bind SDF-1␣. This is now under investigation in our laboratory.
In addition to transcriptional regulation of chemokine expression following cytokine exposure and release by environmental stimuli (49) the maintenance of tissue levels of chemokines is greatly facilitated by interactions with GAGs that "freeze" chemotactic gradients in the extracellular matrix. Chemokine association with GAGs has been well established for SDF-1␣ (50) . A recent report has identified the C-terminal regions of SDF-1␣ that are responsible for GAG interaction and the mechanism for GAG-mediated presentation of the free N terminus of SDF-1␣ to CXCR-4 (40) . MMP-2 is also known to bind heparin sulfate via the hemopexin C domain (32) . In the presence of molar excess GAGs, SDF-1␣ was still processed by MMPs to release the N-terminal tetrapeptide. This is an important finding as the in vivo activity of SDF-1␣ is tightly linked to its GAG-binding properties, and in this GAG-bound form our data shows that SDF-1␣ retains MMP cleavage susceptibility.
The in vivo role of SDF-1 processing by MMPs remains to be elucidated. However, our biochemical and cell culture data shows the potency of cleavage and inactivation of SDF-1 by multiple MMPs indicating that in physiological or pathological situations MMP activity has the potential to modulate multiple cellular processes mediated by SDF-1. A physiological consequence of MMP cleavage of SDF-1␣ may be to reduce the protective effects of SDF-1 in modulating HIV infection. Indeed, induction of MMP expression by HIV (47) leading to SDF-1 cleavage may be a virulence factor to increase infectivity. Together, this suggests the potential of MMP inhibitor drugs for novel therapeutic uses in AIDS.
The mobilization and timed release of mature leukocytes and stem cells from the bone marrow may also be regulated by MMP activities. SDF-1␣ is involved in the homing and retention of early progenitor cells, in particular the migration of CD34 ϩ hematopoietic progenitor stem cells between the fetal liver and bone marrow during development and maturation (52) . In mature animals the cytokine-stimulated release of CD34 ϩ cells from the bone marrow is correlated with a signif- icant increase in MMP expression, notably MMP-2 (46). Although it has been previously hypothesized that increased MMP expression facilitates chemotaxis of these cells across basement membranes by matrix degradation (51) we suggest that this increase may be primarily important in the processing of SDF-1␣ to an inactive form that induces the transient release of this population of cells into the circulation. Overall, the studies reported here reveal that MMP processing of chemokines is not limited to the CC-family and indicate that the intersection between the chemokine and MMP networks is broad with potentially important biological consequences. In particular, the inactivation of SDF-1 by multiple MMPs suggests a novel mechanism for the regulation of SDF-1 function in physiological and pathological situations.
